Chinook Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Chinook Therapeutics wird ein Gewinn- und Umsatzwachstum von 22.6% bzw. 63.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 28% pro Jahr wachsen soll.

Wichtige Informationen

22.6%

Wachstumsrate der Gewinne

28.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	63.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	10 Aug 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

May 28

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

Feb 14

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Aug 31

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Aug 12

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Aug 08

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

Jul 05

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:KDNY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	80	-247	-286	-253	8
12/31/2024	13	-284	-289	-262	11
12/31/2023	3	-253	-290	-243	5
6/30/2023	6	-246	-177	-174	N/A
3/31/2023	5	-216	-146	-143	N/A
12/31/2022	6	-188	-119	-117	N/A
9/30/2022	57	-118	-105	-103	N/A
6/30/2022	54	-92	-104	-103	N/A
3/31/2022	54	-97	-101	-99	N/A
12/31/2021	52	-103	-105	-103	N/A
9/30/2021	1	-160	-124	-122	N/A
6/30/2021	1	-149	-105	-104	N/A
3/31/2021	1	-114	-82	-80	N/A
12/31/2020	1	-82	-57	-56	N/A
9/30/2020	N/A	-52	-19	-19	N/A
6/30/2020	N/A	-54	-17	-16	N/A
3/31/2020	N/A	-48	-16	-15	N/A
12/31/2019	N/A	-47	-14	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KDNY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KDNY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KDNY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KDNYDie Einnahmen des Unternehmens (63.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: KDNYDie Einnahmen des Unternehmens (63.8% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KDNY in 3 Jahren voraussichtlich hoch sein wird

Chinook Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.8% to US$39.45

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

Consensus revenue estimates increase by 27%, EPS downgraded

Consensus forecasts updated

Consensus revenue estimates fall by 14%

Recent updates

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from NASDAQ Biotechnology Index

Chinook Therapeutics, Inc.(NasdaqGS:KDNY) dropped from S&P TMI Index

Second quarter 2023 earnings released: US$0.94 loss per share (vs US$0.61 loss in 2Q 2022)

Chinook Therapeutics, Inc. Announces the First Patient Enrolled in its Phase 3 Second Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Chinook Therapeutics, Inc. Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failure Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

Price target increased by 7.8% to US$39.45

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

New major risk - Share price stability

Will Chinook Therapeutics (NASDAQ:KDNY) Spend Its Cash Wisely?

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 273%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

President notifies of intention to sell stock

Independent Lead Director recently sold US$6.1m worth of stock

Chief Scientific Officer exercised options and sold US$57k worth of stock

Consensus revenue estimates increase by 27%, EPS downgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$192k worth of stock

Chinook Therapeutics, Inc. Appoints Andrew Oxtoby as Chief Commercial Officer

Companies Like Chinook Therapeutics (NASDAQ:KDNY) Are In A Position To Invest In Growth

President recently sold US$190k worth of stock

Chief Scientific Officer exercised options and sold US$191k worth of stock

Chief Operating Officer exercised options and sold US$246k worth of stock

President exercised options and sold US$657k worth of stock

Consensus forecasts updated

Chief Operating Officer notifies of intention to sell stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Operating Officer exercised options and sold US$217k worth of stock

Chinook Therapeutics, Inc. Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022

Chief Operating Officer exercised options and sold US$145k worth of stock

Independent Director recently bought US$212k worth of stock

Chinook Therapeutics: Multiple Shots On Goal For IgAN

Consensus revenue estimates fall by 14%

Analysts Have Just Cut Their Chinook Therapeutics, Inc. (NASDAQ:KDNY) Revenue Estimates By 17%

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

Chief Scientific Officer exercised options and sold US$98k worth of stock

Chief Scientific Officer exercised options and sold US$89k worth of stock

Chinook gets European orphan drug designation for BION-1301 for a type of kidney disease

High number of new directors

President recently bought US$65k worth of stock

Consensus forecasts updated

Price target increased to US$34.86

Chinook Therapeutics, Inc. Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at 59th European Renal Association Congress 2022

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

High number of new directors

Chinook Therapeutics, Inc., Annual General Meeting, May 26, 2022

Chief Scientific Officer exercised options and sold US$75k worth of stock

Chinook Therapeutics Announces Initiation of Phase 1 Healthy Volunteer Trial of CHK-336, a First-in-Class LDHA Inhibitor to Treat Hyperoxalurias

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Chinook Therapeutics, Inc. Announces Resignation of Alan Glicklich as Chief Medical Officer, Effective February 11, 2022

High number of new directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken